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Abstract
The microscopic observation drug susceptibility assay (MODS) was evaluated to determine susceptibility to pyrazinamide in Mycobacte-
rium tuberculosis, and compared with the broth microdilution method (BMM), absolute concentration method (ACM), and pyrazinami-
dase (PZase) determination. We tested 34 M. tuberculosis clinical isolates (24 sensitive and eight resistant to pyrazinamide) and the
control strains M. tuberculosis H37Rv (ATCC 27294) and Mycobacterium bovis AN5. The MODS, BMM, ACM and PZase determination
provided results in average times of 6, 18, 28 and 7 days, respectively. All methods showed excellent sensitivity and speciﬁcity
(p <0.05). Of the methods studied, the MODS proved to be faster, efﬁcient, inexpensive, and easy to perform. However, additional
studies evaluating the MODS in differentiating pyrazinamide-resistant and pyrazinamide-susceptible M. tuberculosis must be conducted
with a larger number of clinical isolates.
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Introduction
Tuberculosis (TB) is a worldwide health problem. It is esti-
mated that 9.27 million cases occurred in 2007, and approxi-
mately 15% of these involved co-infection with human
immunodeﬁciency virus [1]. Pyrazinamide is an important drug
that is used in combination with isoniazid, rifampicin and eth-
ambutol in the ﬁrst-line treatment of TB [2]. Pyrazinamide
needs to be converted to pyrazinoic acid by pyrazinamidase
(PZase), which is effective against a population of semidormant
Mycobacterium tuberculosis in the acid environment inside mac-
rophages that cannot be reached in vivo by other drugs [3].
Pyrazinamide susceptibility testing in vitro is somewhat dif-
ﬁcult to perform, because the acid pH of the medium
required to maintain drug activity inhibits bacterial growth
[4]. Conventional pyrazinamide susceptibility testing by the
Lowenstein–Jensen (L-J) proportion method is most often
used for M. tuberculosis, but this technique requires a mini-
mum of 3–4 weeks to produce results [5,6]. Furthermore,
we need to consider the fact that when the drug is included
in the L-J medium and exposed to high temperature (85C)
during the preparation of the medium, its potency may be
reduced [7].
New methods have been proposed recently for M. tuber-
culosis susceptibility testing, including the resazurin microtitre
assay plate [8], the microplate Alamar Blue assay [9], the 3-
(4,5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bromide
assay [10], the broth microdilution method (BMM) [11], and
the microscopic observation drug susceptibility assay
(MODS) [12,13]. These methods have the advantage of using
a liquid medium, which can provide results in a shorter
time.
The MODS [12] is fast and easy to perform. It also has a
low cost and allows simultaneous detection of the bacilli and
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the incorporation of drugs for the susceptibility testing. The
method is based on the principle that M. tuberculosis grows
faster in a liquid medium, and its characteristic growth ‘cord-
ing formation’ can be observed through an inverted light
microscope [12–15]. Several studies have used the MODS to
determine susceptibility to isoniazid and rifampicin
[12,13,15–17], and it seems to be reliable as compared with
the reference method. However, it has not been applied to
detect susceptibility to pyrazinamide.
The aim of our study was to evaluate the application of
the MODS for the determination of susceptibility to pyrazin-
amide in M. tuberculosis, and to compare it with the BMM,
the absolute concentration method (ACM), and determina-
tion of PZase activity.
Materials and Methods
Mycobacterial strains
The pyrazinamide-susceptible strain M. tuberculosis H37Rv
(ATCC 27294) and the pyrazinamide-resistant strain
Mycobacterium bovis AN5 were used as controls in the
susceptibility test for pyrazinamide. Mycobacterium avium
(ATCC 13950) and M. bovis AN5 were used as positive and
negative controls, respectively, for determination of PZase
activity.
A total of 32 M. tuberculosis clinical isolates were selected
from the mycobacteria collection of the Clinical Bacteriology
Laboratory in the Clinical Analysis and Biomedicine Depart-
ment of Maringa´ State University. Of these isolates, 24 were
susceptible and eight were resistant to pyrazinamide, as
assessed by the proportion method in L-J medium (pH 5.5)
with a pyrazinamide concentration of 100 mg/L as a cut-off
for resistance [18]. Automated DNA sequencing of a 1200-
bp segment including the entire pncA open reading frame, as
well as its regulatory region, was previously carried out [19]
in pyrazinamide-resistant M. tuberculosis isolates.
Pyrazinamide solution
A stock solution of 20 000 mg/L pyrazinamide (Sigma,
St Louis, MO, USA) in distilled water was prepared, ﬁlter-
sterilized, and stored at )20C until use. At the time of use,
the stock solution was diluted to give the MICs for the
MODS, BMM, and ACM.
MODS
The MODS was performed as previously described [16] in
24-well sterile plates (TPP, Trasadingen, Switzerland), in trip-
licate. Middlebrook 7H9 medium (Difco Laboratories,
Detroit, MI, USA) supplemented with OADC Enrichment
(BBL/Becton-Dickinson, Sparks, MD, USA) was prepared as
previously described [12], and the pH was adjusted to 6.0
[19]. One millilitre of drug-free medium was added to each
well, and the pyrazinamide stock solution was diluted to
obtain ﬁnal concentrations of 6.25–3200 mg/L. One hundred
microlitres of mycobacterial inoculum, previously standard-
ized according to 1 McFarland turbidity and diluted to 10)3
[16], was inoculated into each well of drug-containing med-
ium, and also into the wells of the mycobacterial control.
Each plate was covered with its lid and sealed along its edge
with polyethylene tape. The plates were placed in a plastic
bag to prevent evaporation, and incubated at 35C in normal
atmosphere. Mycobacterial growth was observed daily with
an inverted light microscope at ·40 magniﬁcation (Olympus,
CK 40) from the 3rd to the 15th day of incubation [13,16].
Mycobacterial growth was deﬁned as the emergence of visu-
ally characteristic serpentine growth. The MIC results were
interpreted on the day when distinct growth could be
observed in the control wells for each M. tuberculosis isolate.
The isolates that showed MICs £100 mg/L were considered
to be susceptible to pyrazinamide [19].
BMM
The BMM was performed as previously described [11], in trip-
licate. First, 200 lL of distilled water was added to the outer
wells of the 96-well microplates (Kartell, Milan, Italy). One
hundred microlitres of Middlebrook 7H9 medium (Difco Lab-
oratories), supplemented with OADC Enrichment (BBL/Bec-
ton-Dickinson) and with the pH adjusted to 6.0 [19], was
added to each well. The pyrazinamide stock solution was
diluted to obtain concentrations from 12.5 to 3200 mg/L. Five
microlitres of bacterial inoculum standardized to 0.5 McFar-
land turbidity and further diluted to 10)2 [11] was inoculated
into the wells of drug-containing media and also into the con-
trol wells. Each plate was covered with its lid and sealed along
its edge with polyethylene tape. The plates were placed in a
plastic bag to prevent evaporation, and incubated at 35C in a
normal atmosphere. The readings were made after 14, 20 and
28 days of incubation through visual observation of the
growth. The MIC was deﬁned as the lowest pyrazinamide con-
centration that exhibited no growth by visual reading, and the
isolates were considered to be susceptible to pyrazinamide if
their MICs were £100 mg/L [19].
ACM
The ACM was performed in triplicate in L-J medium (Difco
Laboratories). The L-J medium was prepared according to
the manufacturer’s instructions, and the pH was adjusted to
5.2 with sterile 5 M hydrochloric acid (Quimex, Sa˜o Paulo,
Brazil) [5]. The pyrazinamide stock solution was diluted to
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obtain concentrations from 6.25 to 3200 mg/L, and the med-
ium was subjected to coagulation for 45 min at 85C. One
hundred microlitres of standardized bacterial inoculum with
Mcfarland turbidity 1 and further diluted to 10)3 in saline
was inoculated onto L-J slant medium containing different
pyrazinamide concentrations. A mycobacterial growth con-
trol for each M. tuberculosis isolate was carried out in L-J
slant medium, at pH 5.2 and 6.8 without pyrazinamide [19].
All media were incubated at 35C for 28 days and inspected
weekly. The MIC was expressed in terms of the lowest con-
centration of the drug that inhibited mycobacterial growth.
Isolates showing MICs £100 mg/L were considered to be
susceptible [19].
Determination of PZase activity
PZase activity was assayed qualitatively as previously
described [5], with Dubos broth medium (Difco Laborato-
ries) containing 100 mg/L pyrazinamide. The test was per-
formed in duplicate for each M. tuberculosis isolate, and
incubated at 35C for 7 and 14 days. The tests were read by
addition of 1 mL of freshly prepared 1% ferrous ammonium
sulphate solution (Quimibra´s, Rio de Janeiro, Brazil) and
maintained at room temperature for 1 h. The test result was
considered to be positive for PZase activity if a pink band
appeared in the agar medium.
Statistical analysis
The software EpiInfo (Centers for Disease Control and Pre-
vention, Atlanta, GA, USA), version 3.32, was employed to
analyse the data, at a signiﬁcance level of 5%. The associa-
tions of the MODS and BMM and PZase activity were
assessed by Fisher’s exact test.
Results
The MIC, PZase activity and pncA mutation results for the
clinical M. tuberculosis isolates resistant to pyrazinamide are
listed in Table 1. The pyrazinamide-resistant M. tuberculosis
isolates showed MICs ‡3200 mg/L and ‡800 mg/L by the
MODS and the ACM, respectively. The BMM detected six
(75%) resistant isolates, with MICs ‡800 mg/L. Two resistant
isolates did not show growth by this method.
Twenty-one (87.5%) of 24 pyrazinamide-susceptible
M. tuberculosis clinical isolates showed growth by the MODS,
22 (91.6%) by the BMM, and 24 (100%) by the ACM. All of
the susceptible isolates showed MICs £100 mg/L (Table 2).
The PZase test gave positive results for all pyrazinamide-
susceptible isolates and for one pyrazinamide-resistant
M. tuberculosis isolate (Tables 1 and 2).
MIC results were available within a mean of 6.6 days
(range, 4–15 days) for the MODS, 18 days (range, 14–
28 days) for the BMM, and 28 days for the ACM. The MIC
results were obtained in 7 days for 82.8% of the isolates
tested by the MODS, and in 14 days for 62.8% of the iso-
lates tested by the BMM (Table 3).
TABLE 1. MICs for pyrazinamide, pyrazinamidase (PZase)
activity and pncA mutations in pyrazinamide-resistant clini-
cal isolates of Mycobacterium tuberculosis and control strains
(M. tuberculosis H37Rv and Mycobacterium bovis AN5)
Isolates
Pyrazinamide MIC (mg/L)
PZase
pncA mutations
MODS BMM ACM N AA
H37Rv 100 £12.5 100 + NM NM
AN5 >3200 >3200 >3200 ) G169C H57N
3614 3200 1600 1600 ) T464G V155E
69A >3200 >3200 >3200 ) A287C K96T
15109 >3200 800 1600 ) T490C S164P
1137 >3200 NG 800 ) T359G L120R
73A >3200 800 1600 ) T175C S59P
3224 >3200 NG 800 + NM NM
71A >3200 800 1600 ) A11G NA
5505 >3200 >3200 >3200 ) Deletion
AA, amino acid changes in pyrazinamidase; ACM, absolute concentration
method; BMM, broth microdilution method; MODS, microscopic observation
drug susceptibility assay; N, nucleotide changes in the pncA gene; NA, not appli-
cable; NG, no growth; NM, no mutation.
TABLE 2. MICs for pyrazinamide and pyrazinamidase
(PZase) activity in pyrazinamide-susceptible clinical isolates
of Mycobacterium tuberculosis and control strains (M. tuber-
culosis H37Rv and Mycobacterium bovis AN5)
Isolates
Pyrazinamide MIC (mg/L)
PZaseMODS BMM ACM
H37Rv 100 £12.5 100 +
AN5 >3200 >3200 >3200 )
1264 100 100 100 +
1118 100 100 12.5 +
23657 6.25 25 100 +
1s 50 12.5 100 +
3s 100 12.5 100 +
4s 100 50 100 +
5s 100 12.5 100 +
7s 12.5 12.5 100 +
9s 6.25 12.5 25 +
10s 6.25 12.5 100 +
13s 12.5 12.5 100 +
14s 12.5 12.5 100 +
16s 25 12.5 100 +
TB 19 100 12.5 100 +
TB 27 NG 12.5 100 +
TB 40 100 50 50 +
TB 43 NG 12.5 100 +
TB 46 12.5 25 100 +
TB 49 12.5 12.5 100 +
TB 54 6.25 12.5 100 +
TB 57 6.25 12.5 100 +
TB 71 50 12.5 100 +
TB 80 NG 12.5 100 +
Mga´01 12.5 12.5 100 +
ACM, absolute concentration method; BMM, broth microdilution method;
MODS, microscopic observation drug susceptibility assay; NG, no growth.
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The performance of the MODS, the BMM and PZase
determination for detection of resistance to pyrazinamide
was determined when selecting the ACM as standard. The
MODS and the BMM sensitivity and speciﬁcity were com-
plete (100%). For PZase activity, they were 87.50% and
100%. There was no signiﬁcant difference among the tests
(p <0.05) (Table 3).
Discussion
Although pyrazinamide is a ﬁrst line anti-TB drug used in the
ﬁrst 2 months of TB treatment, the susceptibility test for
pyrazinamide in M. tuberculosis poses some difﬁculties,
because it has low reproducibility, owing to the drug being
active only in a relatively low-pH medium [4]. This low-pH
environment may decrease the colony count by nearly 50%
for M. tuberculosis as compared with a neutral pH environ-
ment, in the proportion method [18]. Pyrazinamide is very
important in TB treatment, because it has a sterilizing effect
by killing M. tuberculosis in the acid environment during active
inﬂammation. In this sense, it is very important to have a
fast, sensitive and easy susceptibility test for pyrazinamide, to
be carried out not only before treatment, but mainly in the
course of the treatment for the management of multidrug-
resistant TB [20].
In the present study, the introduction of the MODS
(pH 6.0) for the detection of susceptibility to pyrazinamide
in M. tuberculosis showed 100% agreement with the ACM.
Although the number of pyrazinamide-resistant isolates eval-
uated was small (n = 8), all of them showed MICs ‡800 mg/L
by the MODS and the ACM. Mengatto et al. [16], comparing
the MODS with the proportion method to detect suscepti-
bility to isoniazid at concentrations of 0.1 and 0.4 mg/L,
obtained 100% and 88% agreement, respectively. For rifampi-
cin, these authors obtained 100% agreement for the concen-
trations of 1 and 0.5 mg/L.
An important factor in detection of the susceptibility of
M. tuberculosis to the drugs available to treat TB is the time
needed to read the test. The MODS showed a mean time of
6.6 days for the detection of pyrazinamide susceptibility, and
was faster than the BMM and the ACM, which required, on
average, 18 and 28 days, respectively.
One of the advantages of using the MODS to detect pyr-
azinamide susceptibility is the ease of reading the test. The
growth of M. tuberculosis is detected by observation of the
characteristic growth in a cording formation, which requires
only an inverted light microscope [12]. It is not necessary to
use sophisticated equipment or reagents, making it easier to
use the susceptibility test in laboratories with limited ﬁnan-
cial resources, particularly in developing countries, where
the rates of multidrug-resistant TB and extremely drug-resis-
tant TB are increasing [1]. It is important to emphasize that
the same safety precautions as used to perform cultures in
liquid medium are necessary for reading the MODS, and the
plates must be sealed when the test is read, in order to
decrease the risk of aerosol formation.
In our study, we observed that MICs in the BMM [11]
were generally lower than those obtained by the ACM. One
pyrazinamide-susceptible and two pyrazinamide-resistant iso-
lates showed no growth by this method. Both situations, the
non-mycobacterial growth and the lower MIC values, can be
explained by the difﬁculty in obtaining mycobacterial growth
in Middlebrook 7H9 at pH 6.0, and also the subjectivity in
the reading test, which is based on visual observation of
growth. Another disadvantage of the BMM for pyrazinamide
susceptibility detection is the time needed to read the test,
which averaged 18 days.
Mengatto et al. [16] obtained good results with the BMM
for the detection of susceptibility to isoniazid and rifampicin,
with a sensitivity higher than 90% as compared with the pro-
portion method in L-J medium. On the other hand, the
results for streptomycin, and especially for ethambutol,
showed lower agreement. In general, depending on the
method used, the MIC values were not equal, although they
showed little difference, but this does not change the suscep-
tibility categorization. This ﬁnding may be explained by differ-
ences in the mycobacterial inoculum, medium, and time of
reading, and whether visual or microscopy observation was
used.
TABLE 3. Performance and detection time of the microscopic observation drug susceptibility assay (MODS), the broth micro-
dilution method (BMM), and pyrazinamidase (PZAse) activity as compared with the absolute concentration method
Method
Relative sensitivity,
% (95% CI), n
Relative speciﬁcity,
% (95% CI), n
Agreement,
% (95% CI), n p-Valuea
Time
(days)
MODS 100 (68.77–100.00), 29 100 (86.71–100.00), 29 100 (90.19–100.00), 29 0.000000233 6.6
BMM 100 (60.70–100.00), 30 100 (88.27–100.00), 30 100 (90.50–100.00), 30 0.000001684 18
PZase 87.50 (51.97–99.37), 32 100 (88.27–100.00), 32 96.88 (85.54–99.84), 32 0.000002377 7
aMid-p exact test.
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The determination of PZase activity is intimately related
to resistance to pyrazinamide. The lack of this enzyme in the
bacillus prevents pyrazinamide from being converted into
pyrazinoic acid and then conferring resistance on the
M. tuberculosis complex [21]. Mutations in pncA, coding for
PZase, may provide resistance to pyrazinamide, owing to
non-conversion of the pyrazinamide to its active metabolite
by PZase [22,23]. All of the pyrazinamide-susceptible
M. tuberculosis isolates tested in our study were positive for
PZase activity. Of the eight clinical isolates characterized as
resistant to pyrazinamide, seven (87.5%) had negative results
for PZase activity, and had pncA pontual mutations or even
total deletion of the gene. Other studies [19,22–24] have
also found a relationship between the presence of a mutation
in pncA and negative results for PZase activity. Only one pyr-
azinamide-resistant isolate was positive for PZase activity,
despite showing an MIC value characterized as resistant by
the MODS (>3200 mg/L) and the ACM (>800 mg/L). The
same isolate did not grow in the BMM. This pyrazinamide-
resistant isolate did not have mutations in pncA and its regu-
latory region [19], which leads us to consider the possibility
of the existence of other mechanisms of resistance to pyraz-
inamide, such as changes in pyrazinamide uptake or increased
efﬂux of the active drug [19,24–27].
The sensitivity of PZase activity determination found in
our study (87.5%) is similar to levels reported previously
[21,28], indicating that this is an efﬁcient method for the
detection of pyrazinamide resistance in M. tuberculosis. The
great utility of PZase activity determination for the detection
of resistance to pyrazinamide resides in its high speciﬁcity,
rapidity, and ease of performance [21].
Our results show that, of the methods used to detect
susceptibility to pyrazinamide in M. tuberculosis, the MODS
proved to be faster, efﬁcient, inexpensive, and easy to per-
form. Additional studies with larger numbers of isolates
resistant to pyrazinamide and with MIC values lower than
those used in this study will enable a better understanding
of the utility of the MODS in differentiating pyrazinamide-
resistant and pyrazinamide-susceptible M. tuberculosis. Such
studies will enable the application of this method for the
rapid detection of resistance of M. tuberculosis to pyrazina-
mide in clinical laboratories with limited ﬁnancial
resources.
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